Stockreport

Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time [Seeking Alpha]

Gyre Therapeutics, Inc.  (GYRE) 
PDF Gyre focuses on developing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, with a successful drug, Etuary, approved for idiopathic pu [Read more]